

classification was performed according to the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE).

Result(s)* A total of 402 patients with a complete set of bone marrow cytology, molecular and clinical data was evaluable. ProMisE molecular classification revealed 40(10.0%) *POLE*mut, 103(25.6%) MMRd, 52(12.9%) p53-abnormal and 207(51.5%) tumors with no specific molecular profile (NSMP). Overall DTC were detected in 71/402 (17.7%) patients. DTC occurrence was distributed equally among molecular groups ($p=0.651$). DTC were present in 7/40 (17.5%) *POLE*mut, 21/103(20.4%) MMRd, 32/207(15.5%) NSMP and 11/52(21.2%) p53 abnormal tumors.

Conclusion* The scientific community widely agrees that molecular classification will be of key importance in future endometrial carcinoma patient care. In line with our previous findings, tumor cell dissemination is not associated with TCGA-inspired molecular groups in our large cohort of primary endometrial carcinoma patients. While DTC are detectable in a significant number of patients, even including cases with favorable *POLE*mut subtype, tumor cell dissemination seems not to play a role in disease progression and clinical outcome in endometrial carcinoma.

750

DIAGNOSTIC ACCURACY OF SENTINEL NODE BIOPSY IN NON-ENDOMETRIOID, HIGH-GRADE AND/OR DEEP MYOINVASIVE ENDOMETRIAL CANCER (TRSGO-SLN-006)

¹D Altın*, ²S Taşkın, ³N Tokgözoğlu, ⁴D Vatansever, ⁵AH Güler, ⁶M Gungor, ⁷T Taşçı, ⁸T Beşe, ⁹H Turan, ¹⁰I Kahramanoglu, ¹¹J Yalçın, ⁵C Celik, ⁸F Demirkiran, ⁶F Köse, ²FU Ortac, ⁸M Arvas, ¹²A Ayhan, ⁴C Taskiran. ¹Ordu Üniversitesi Eğitim ve Araştırma Hastanesi, Turkey; ²Ankara Üniversitesi Tıp Fakültesi, Turkey; ³Prof. Dr. Cemil Taşcıoğlu Şehir Hastanesi, Turkey; ⁴Koc University, Turkey; ⁵Selçuk University, Turkey; ⁶Acıbadem University School of Medicine, Turkey; ⁷Bahçeşehir Üniversitesi Hastanesi Medical Park Göztepe, Turkey; ⁸Cerrahpaşa Tıp Fakültesi, Turkey; ⁹T C Sağlık Bakanlığı İstanbul Eğitim ve Araştırma Hastanesi, Turkey; ¹⁰Emsey Hastanesi, Turkey; ¹¹Ondokuz Mayıs University, Turkey; ¹²Başkent Üniversitesi Tıp Fakültesi, Turkey

10.1136/ijgc-2021-ESGO.190

Introduction/Background* The aim of this study was to evaluate sensitivity, negative predictive value (NPV) and false negative rate (FNR) of sentinel lymph node (SLN) mapping algorithm in high-risk endometrial cancer patients.

Methodology Patients with non-endometrioid histology, grade 3 endometrioid tumors and/or tumors with deep myometrial invasion were enrolled in this retrospective, multicenter study. After removal of SLNs, all patients underwent pelvic ± para-aortic lymphadenectomy. Operations were performed via laparotomy, laparoscopy or robotic surgery. Indocyanine green (ICG) and methylene blue (MB) were used as tracers. SLN detection rate, sensitivity, NPV and FNR were calculated.

Result(s)* Two hundred forty-four patients were included. Surgeries were performed via open approach in 132 (54.1%) patients. While 92 (37.7%) patients underwent bilateral pelvic lymphadenectomy, 152 (62.3%) underwent both bilateral pelvic and paraaortic lymphadenectomy. ICG was used in 120 (49.2%) patients and MB in 124 (50.8%). At least 1 SLN was detected in 222 (91%) patients with a 65.6% bilateral detection rate. Fifty-five (22.5%) patients had lymphatic metastasis and 45 patients had at least 1 metastatic SLN: 28 macrometastasis, 6 micrometastasis and 11 isolated tumor cells. Lymphatic metastasis was detected by side-specific

Abstract 750 Table 1

	Total (244)	G3 endometrioid/ non-endometrioid (128)	Grade 1-2 Endometrioid + Deep MI (116)
Age, years, median (range)	63.5 (33-87)	63 (37-82)	64.5 (33-87)
BMI, kg/m ² , median (range)	30 (18.6-53)	29.3 (19-53)	31.8 (18.6-49)
Menopausal status, n (%)			
Premenopause	20 (8.2)	11 (8.6)	9 (7.8)
Postmenopause	224 (91.8)	117 (91.4)	107 (92.2)
Surgical route, n (%)			
Laparotomy	132 (54.1)	75 (58.6)	57 (49.1)
Laparoscopy	105 (43)	51 (39.8)	54 (46.6)
Robotic	7 (2.9)	2 (1.6)	5 (4.3)
Lymphadenectomy, n (%)			
BPLND	92 (37.7)	31 (24.2)	61 (52.6)
BPPALND	152 (62.3)	97 (75.8)	55 (47.4)
Dye, n (%)			
ICG	120 (49.2)	68 (53.1)	52 (44.8)
MB	124 (50.8)	60 (46.9)	64 (55.2)
Tm size, mm, median (range)	40 (3-130)	40 (3-130)	40 (8-100)
Histology, n (%)			
Endometrioid	182 (74.6)	66 (51.6)	116 (100)
Serous	23 (9.4)	23 (18)	
Clear cell	6 (2.5)	6 (4.7)	
Carcinosarcoma	17 (7)	17 (13.3)	
Mixed	10 (4.1)	10 (7.8)	
Other	6 (2.5)	6 (4.7)	
Grade, n (%)			
1	34 (13.9)		34 (29.3)
2	82 (33.6)		82 (70.7)
3	128 (52.5)	128 (0)	
Depth of MI, n (%)			
None	8 (3.3)	8 (6.3)	
?1/2	54 (22.1)	54 (42.2)	
>1/2	182 (74.6)	66 (51.6)	116 (100)
LVSI, n (%)			
Absent	132 (54.1)	64 (50)	68 (58.6)
Present	112 (45.9)	64 (50)	48 (41.4)
Cervical stromal invasion, n (%)			
Absent	198 (81.1)	96 (75)	102 (87.9)
Present	46 (18.9)	32 (25)	14 (12.1)
Stage, n (%)			
IA	46 (18.9)	46 (35.9)	
IB	109 (44.7)	23 (18)	86 (74.1)
II	18 (7.4)	10 (7.8)	8 (6.9)
IIIA	11 (4.5)	10 (7.8)	1 (0.9)
IIIC1	31 (12.7)	19 (14.8)	12 (10.3)
IIIC2	22 (9)	14 (10.9)	8 (6.9)
IVB	7 (2.4)	6 (4.7)	1 (0.9)
Lymphatic metastasis, n (%)	55 (22.5)	35 (27.3)	20 (17.2)
SLN metastasis, n (%)	45 (18.4)	29 (22.7)	16 (13.8)

Abstract 750 Table 2

	SLN Biopsy Alone	Overall	SLN Algorithm	
			Grade 3 endometrioid/ non-endometrioid	Grade 1-2 Endometrioid + Deep MI
Sensitivity	81.8%	96.4%	97.1%	95%
NPV	95%	98.9%	98.9%	98.9%
FNR	18.2%	3.6%	2.9%	5%

lymphadenectomy in 8 patients and 2 patients had isolated paraaortic metastasis. Overall sensitivity, NPV and FNR of SLN biopsy were 81.8%, 95% and 18.2%, respectively. By applying SLN algorithm steps, sensitivity and NPV improved to 96.4% and 98.9%, respectively. For grade 3 tumors, sensitivity, NPV and FNR of the SLN algorithm were 97.1%, 98.9% and 2.9%, respectively. Sensitivity, NPV and FNR of SLN algorithm were 95%, 98.9% and 5%, respectively in deep myoinvasive tumors.

Conclusion* This study was performed in one of the largest high-risk endometrial cancer population. SLN algorithm was found to be safe and had high diagnostic accuracy also in high-risk endometrial cancer patients. Although it seems like SLN algorithm is a feasible option for staging, long term studies to determine impact of SLN biopsy alone on survival are needed before it becomes standard of care in high-risk endometrial cancer.